- Home
- HFBL vs OTLK Comparison
HFBL vs OTLK Comparison
Compare HFBL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | OTLK |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HFBL | OTLK |
|---|---|---|
| Price | $17.93 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 5.4K | ★ 13.5M |
| Earning Date | 01-27-2026 | 02-13-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 35.20 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $21,720,000.00 | $1,413,535.00 |
| Revenue This Year | N/A | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $12.31 | $0.50 |
| 52 Week High | $19.20 | $3.39 |
Technical Indicators
Market Signals| Indicator | HFBL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 25.31 |
| Support Level | $17.40 | $0.51 |
| Resistance Level | $17.90 | $0.65 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 86.83 | 2.52 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.